Joseph Schwartz
Stock Analyst at Leerink Partners
(4.07)
# 533
Out of 5,090 analysts
157
Total ratings
33.09%
Success rate
20.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Schwartz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLT Applied Therapeutics | Downgrades: Market Perform | $2 → $1 | $0.22 | +352.28% | 3 | Dec 3, 2025 | |
| SPRB Spruce Biosciences | Upgrades: Outperform | $160 | $80.30 | +99.25% | 7 | Dec 3, 2025 | |
| DSGN Design Therapeutics | Upgrades: Outperform | $7 → $14 | $9.81 | +42.71% | 5 | Dec 3, 2025 | |
| IFRX InflaRx | Downgrades: Market Perform | $5 → $2 | $1.10 | +81.82% | 5 | Dec 3, 2025 | |
| BMRN BioMarin Pharmaceutical | Downgrades: Market Perform | $82 → $60 | $53.64 | +11.86% | 11 | Dec 3, 2025 | |
| AUPH Aurinia Pharmaceuticals | Downgrades: Market Perform | $15 → $16 | $15.09 | +6.03% | 7 | Dec 3, 2025 | |
| QURE uniQure | Maintains: Outperform | $68 → $60 | $22.09 | +171.62% | 3 | Nov 10, 2025 | |
| MNPR Monopar Therapeutics | Initiates: Outperform | $115 | $80.29 | +43.23% | 1 | Nov 10, 2025 | |
| RNA Avidity Biosciences | Downgrades: Market Perform | $65 → $72 | $71.67 | +0.46% | 4 | Oct 27, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $80 → $88 | $47.33 | +85.93% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $12 → $15 | $22.65 | -33.77% | 14 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $20 | $15.99 | +25.08% | 6 | Jul 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $115 | $205.59 | -44.06% | 4 | Jun 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $4 → $12 | $8.77 | +36.83% | 4 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $42.00 | -33.33% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $40 | $34.85 | +14.78% | 6 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.07 | - | 3 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $12 | $6.01 | +99.67% | 6 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $8 | $2.07 | +287.41% | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $1 | $1.14 | -11.89% | 4 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $48 | $76.88 | -37.57% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $18 | $27.70 | -35.02% | 5 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $33 → $34 | $81.08 | -58.06% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $148 → $163 | $208.77 | -21.92% | 15 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $3.35 | +198.51% | 7 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $33 | $5.22 | +532.18% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $115 → $108 | $36.24 | +198.01% | 6 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $30 | $24.16 | +24.17% | 2 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $30 | $88.11 | -65.95% | 6 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $9.94 | +40.85% | 12 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $12 | $2.09 | +474.16% | 2 | Sep 26, 2017 |
Applied Therapeutics
Dec 3, 2025
Downgrades: Market Perform
Price Target: $2 → $1
Current: $0.22
Upside: +352.28%
Spruce Biosciences
Dec 3, 2025
Upgrades: Outperform
Price Target: $160
Current: $80.30
Upside: +99.25%
Design Therapeutics
Dec 3, 2025
Upgrades: Outperform
Price Target: $7 → $14
Current: $9.81
Upside: +42.71%
InflaRx
Dec 3, 2025
Downgrades: Market Perform
Price Target: $5 → $2
Current: $1.10
Upside: +81.82%
BioMarin Pharmaceutical
Dec 3, 2025
Downgrades: Market Perform
Price Target: $82 → $60
Current: $53.64
Upside: +11.86%
Aurinia Pharmaceuticals
Dec 3, 2025
Downgrades: Market Perform
Price Target: $15 → $16
Current: $15.09
Upside: +6.03%
uniQure
Nov 10, 2025
Maintains: Outperform
Price Target: $68 → $60
Current: $22.09
Upside: +171.62%
Monopar Therapeutics
Nov 10, 2025
Initiates: Outperform
Price Target: $115
Current: $80.29
Upside: +43.23%
Avidity Biosciences
Oct 27, 2025
Downgrades: Market Perform
Price Target: $65 → $72
Current: $71.67
Upside: +0.46%
Crinetics Pharmaceuticals
Sep 29, 2025
Maintains: Outperform
Price Target: $80 → $88
Current: $47.33
Upside: +85.93%
Sep 9, 2025
Maintains: Market Perform
Price Target: $12 → $15
Current: $22.65
Upside: -33.77%
Jul 7, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $15.99
Upside: +25.08%
Jun 10, 2025
Maintains: Outperform
Price Target: $100 → $115
Current: $205.59
Upside: -44.06%
May 23, 2025
Upgrades: Outperform
Price Target: $4 → $12
Current: $8.77
Upside: +36.83%
Feb 25, 2025
Initiates: Outperform
Price Target: $28
Current: $42.00
Upside: -33.33%
Oct 11, 2024
Maintains: Outperform
Price Target: $20 → $40
Current: $34.85
Upside: +14.78%
Jul 3, 2024
Upgrades: Outperform
Price Target: n/a
Current: $1.07
Upside: -
Jun 24, 2024
Upgrades: Outperform
Price Target: $12
Current: $6.01
Upside: +99.67%
Jun 20, 2024
Maintains: Outperform
Price Target: $6 → $8
Current: $2.07
Upside: +287.41%
Feb 9, 2024
Downgrades: Market Perform
Price Target: $1
Current: $1.14
Upside: -11.89%
Mar 17, 2023
Initiates: Market Perform
Price Target: $48
Current: $76.88
Upside: -37.57%
Feb 3, 2023
Maintains: Outperform
Price Target: $20 → $18
Current: $27.70
Upside: -35.02%
Feb 3, 2023
Maintains: Market Perform
Price Target: $33 → $34
Current: $81.08
Upside: -58.06%
Jan 17, 2023
Maintains: Outperform
Price Target: $148 → $163
Current: $208.77
Upside: -21.92%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $3.35
Upside: +198.51%
Nov 10, 2022
Maintains: Outperform
Price Target: $40 → $33
Current: $5.22
Upside: +532.18%
Nov 3, 2022
Maintains: Outperform
Price Target: $115 → $108
Current: $36.24
Upside: +198.01%
May 12, 2022
Maintains: Outperform
Price Target: $34 → $30
Current: $24.16
Upside: +24.17%
May 5, 2022
Maintains: Outperform
Price Target: $50 → $30
Current: $88.11
Upside: -65.95%
Feb 24, 2022
Maintains: Outperform
Price Target: $16 → $14
Current: $9.94
Upside: +40.85%
Sep 26, 2017
Maintains: Outperform
Price Target: $10 → $12
Current: $2.09
Upside: +474.16%